July 19, 2021
“Ambrx Biopharma (AMAM)… This new biopharma stock has a Strong Buy rating from the analyst consensus, based on 3 positive reviews so far. The shares are priced at $19.56 and their $39.50 average target suggests room for an upside of 101%… Continue Reading…
Recent Comments